F O C U S O N S T R E S S p e r s p e c t i v e
In our ongoing efforts to advance understanding of human diseases, translational research across rodents and humans on stress-related mental disorders stands out as a field that is producing discoveries that illuminate mechanisms of risk and pathophysiology at a brisk rate. Here we offer a Perspective on how a productive translational research dialog between preclinical models and clinical studies of these disorders is being powered by an ever-developing appreciation of the shared neural circuits and genetic architecture that moderate the response to stress across species. Working from these deep foundations, we discuss the approaches, both traditional and innovative, that have the potential to deliver a new generation of risk biomarkers and therapeutic strategies for stress-related disorders.
The ubiquity of stress and stress-related illness All organisms must overcome some adversity to survive and thrive in unpredictable and often unforgiving environments. The ubiquity of stress has shaped highly conserved biological machinery that functions to acutely mobilize bodily resources and generate responses to myriad environmental dangers that threaten injury or death. Higher animals, in particular, have evolved elaborate physio logical and neurobiological systems to perceive, react and adapt to psychological stressors.
Central to these systems is the hypothalamicpituitaryadrenal (HPA) axis, activation of which directs energy away from routine homeostatic functions, such as immunity and tissue repair, to processes such as increased cardiovascular activity and glucose metabolism that are necessary for immediate survival. In the brain, highly complex neu ral circuits distributed in cortical, limbic and midbrain areas integrate, encode and establish memories of stressful stimuli and events to guide future behaviors 1 . The functional dynamics of these circuits are modu lated, in turn, by equally complex and intersecting molecular signaling cascades and by the genes that encode their constituent components. Across species, the capacity of neural and neuroendocrine systems to mount an appropriate response to stress is a core facet of adaptive suc cess and can even build resilience to subsequent stress challenges.
But stress has a dark side. Mental illnesses directly linked to stress, including anxiety disorders, depressive disorders and the newly categorized trauma and stressorrelated disorders (which we hereafter refer to by the earlier diagnostic label of posttraumatic stress disorder or PTSD) 2 , are now so widespread that their prevalence rivals those of emerging global health pandemics such as obesity 3 . The diagnostic symptoms of stressrelated disorders are many and varied, but what they typically have in common is an excessive reaction to isolated or recurring stressful experiences that persists over time, such that it becomes difficult for the sufferer to lead a normal life.
What goes awry in the body and brain when the response to stress stops being a healthy reaction to life's inevitable challenge and starts to become a chronic illness? Why do seemingly similar stressors and stressful life histories make one person sick, but leave another unaf fected? And how can we leverage an everincreasing understanding of the brain and behavior to design new ways to alleviate the suffering of people afflicted by stressrelated illness and, ultimately, prevent them altogether?
These are longstanding questions that continue to occupy the work of psychologists, neuroscientists and geneticists. The more circumscribed focus of our Perspective is to highlight the growing potential for marrying preclinical work, predominantly in rodents, with studies in healthy humans and clinical populations. Though the need for greater translational efforts is a common refrain across all of psychiatry, we believe that stress research, with its rich and illus trious history (Fig. 1) , offers a particularly promising opportunity to integrate research at the bench, in the laboratory and in the clinic to provide real advances in our understanding of the biological basis of stressrelated disorders and illuminate a clear path to new strategies for their treatment and prevention.
Stress recruits highly conserved biological machinery
Translational research on stressrelated disorders is predicated on the existence of highly conserved biological machinery functioning to deal with the challenges encountered in the environment. Efforts to find translational applications of stress research are not new and can be traced back to the seminal research of the endocrinologist Hans Selye 4 . Selye's work was the genesis for the systematic study of stress manifest as both a critical adaptive physiologic response to the environment (eustress) and a maladaptive, nonspecific dysregulation of this same physiology (distress or toxic stress). In addition to detail ing numerous effects of stress on the body, Selye identified the HPA axis as the anatomical brainbody substrate of the stress response and demonstrated the powerful regulatory role of glucocorticoid signaling in regulating this response 5 .
A large component of stress research since then has focused on the importance of glucocorticoid signaling in mediating the adaptive and maladaptive effects of stresstriggered HPAaxis activity on the brain 6, 7 . This work reveals how dysregulated glu cocorticoid signaling in animals subjected to chronic stress and in Finding translation in stress research p e r s p e c t i v e humans suffering from stressrelated mental disorders is a nexus through which genetic and environmental risk impairs neural circuit functions to cause aberrant behavior. A wide array of stressors can produce such effects, ranging from the direct physical and chemical insults studied by Selye to more indirect and insidious stressors such as environmental instability. In fact, we now know that witnessing of traumatic events, nonphysical forms of childhood neglect and low levels of perceived social support are types of commonly encountered stressors experienced by individuals who go on to develop anxiety disorders or PTSD.
We also now have a deep understanding of how the brain perceives and processes these experiences. A tripartite corticolimbic circuit comprising the amygdala, hippocampus and prefrontal cortex (PFC) operates across species to regulate both the immediate response and the longterm impact of stress 8, 9 . The amygdala is a highly con served brain structure with multiple functions 10, 11 , the best known of which is to detect potential danger, mount physiologic and behav ioral responses to avoid these threats, and establish lasting memories to predict, and appropriately direct, behavior in the face of future threats. A series of studies dating back to the 1960s provided the first evidence that the amygdala regulated the HPA axis via projections to the paraventricular nucleus 12, 13 . The critical importance of the amygdala in the generation of cueelicited or learned fear responses in rats was subsequently described in the early 1970s by Blanchard and Blanchard 14 -an observation replicated in many different settings in the years since 15 . In recent times, the field has been extraordinarily active in its efforts to delineate the subregions and neuronal sub populations in the rodent amygdala that mediate both learned fear behaviors and the extinction of these responses 8, 16 .
The hippocampus and PFC are often considered to play support ing, but no less integral, roles to the amygdala in stress regulation. Two major contributions of the hippocampus in this regard are the encoding of complex, multisensory (that is, contextual) environmen tal information associated with threat and the provision of an impor tant source of negative feedback to the HPA axis via glucocorticoid receptors. This is evidenced by the observation that rodents with hippocampal lesions fail to use context to adaptively gate responses to threat cues 17, 18 and exhibit elevated circulating levels of the gluco corticoid corticosterone after stress challenge 19 . With regard to the PFC, various subregions in the rodent (for example, anterior cin gulate, prelimbic and infralimbic cortices) gate learned associations between cues and threat, but in some cases only in distinct settings, such as when associations have been extinguished or were formed in the remote past [20] [21] [22] [23] . These findings illustrate how the amygdala, hippocampus and PFC operate in a highly integrated neural circuit, along with critical input from other brain regions, including midbrain monoaminergic nuclei and the thalamus 24, 25 , to filter the immediate and lasting impact of stress.
One of the major pillars of translational research on stress is the highly conserved nature of these brain circuits 26 . Clinical lesion and neuroimaging studies in humans dating back some 20 years demonstrate a prominent role for the human amygdala in process ing and learning about sources of threat 27, 28 . Moreover, patients with stressrelated disorders such as PTSD have been shown to dis play hyperactivity of the amygdala during fear conditioning and extinction, which correlates with their sustained levels of fear [29] [30] [31] .
In a similar vein, some of the welldefined functions of the rodent hippocampus and PFC map onto analogous stressrelated functions in humans 21, 32 . For example, functional neuroimaging studies in healthy humans have shown that the hippocampus is active during contextual processing of threat 33 and that both the hippocampus and PFC are recruited during fear extinction 34, 35 . And in clinical popula tions, such as individuals with PTSD, deficiencies in extinction are closely linked to hypoactivity of the hippocampus (and ventrome dial) PFC 31, 36 , as has been observed in rodents 37 . The clear functional convergence of these and other welldefined stressrelated pro cesses is a boon to the crossfertilization of parallel research streams in rodents and humans. Marina Corral Spence/Nature Publishing Group Figure 1 A brief timeline of some major milestones-past, present and future-related to the observation, classification and scientific study of stress and stress-related disorders. EPM, elevated plus maze; LD, light/dark exploration test; RDoC, research domain criteria. 
The genetic architecture of stress moderation Identifying the molecular mechanisms through which this conserved neural circuitry is modulated brings us one step closer to understanding the pathophysiology of stressrelated disorders and, ultimately, to developing more effective therapeutic targets. Hence, a cornerstone of translational research is the identification of DNA sequence variation in organismal genomes that contribute to variability in the function ing of stressmodulating molecules 38, 39 .
To date, some of the most influential research in this area has not resulted from the sequencing of the reference human genome, as many had expected, but rather from the targeted study of candidate genes. In 1995, Lesch, Murphy and colleagues first described the exist ence of common functional DNA sequence variation in the human gene encoding the serotonin transporter (SLC6A4). This gene was targeted because the serotonin transporter regulates a neurotrans mitter system long implicated in stress 40 . The authors' findings that SLC6A4 variation associates with differences in trait anxiety across individuals represented a watershed not only for translational stress research but also for psychiatric genetics and imaging genetics 41 . This discovery was also instrumental in providing the impetus for the gen eration of rodent strains with functional mutations of the serotonin transporter 42, 43 . These rodent studies helped parse the neural circuit consequences of disrupting the serotonin transporter, stimulating work on the neural correlates of SLC6A4related anxiety and threat processing in humans 44 . Although defining the precise role of the SLC6A4 variant has proven contentious over the years, the type of research it stimulated remains a guide for a rational translational approach to the study of stressrelated disorders.
A recent illustration of this approach is the case of fatty acid amide hydrolase (FAAH), a regulatory component of the brain endocan nabinoid anandamide, which has been tied to stressrelated behav iors and disorders by clinical and pharmacological studies alike [45] [46] [47] [48] . A singlenucleotide polymorphism (SNP) in the human FAAH gene was found to be associated with reduced mRNA expression, enhanced fear extinction and lower scores on PTSDrisk personal ity traits in healthy subjects 49 . At the neural level, imaging genetics studies mapped this phenotype to a capacity of the amygdala to rapidly habituate to threat 50, 51 . Further insight into how this genetic variant might influence amygdala function to affect behav ior followed from rodent pharmacological studies, which mimicked the effects of the lowfunctioning human gene variant by inhibiting FAAH activity. This, in turn, led to the demonstration that decreasing FAAH activity enhanced fear extinction and protected against the damaging effects of chronic stress on the amygdala 52 . In parallel, studies in mice engineered to carry the lowfunctioning human FAAH variant indi cated that the resultant improvement in extinction produced by this genetic mutation was associated with increased functional coupling between the amygdala and PFC 49 . These multiple lines of evidence point toward a model whereby genetically driven variation in FAAH signaling titrates anandamide levels in the amygdala and PFC to moderate stressrelated behavior. More generally, this work exem plifies how the dynamic back and forth between rodent and human studies can not only nominate new candidate genes but also stimulate novel directions for drug development.
Another recent example illustrates the way that candidate genes can be studied to provide a rich biological understanding of how genetic variants work through cellular signaling cascades and brain circuits to impart their effects on stressrelated behaviors. Common genetic polymorphisms in FKBP5 (encoding FK506 binding protein 51) have been found to predict the occurrence of PTSD symptoms in people who had experienced varying degrees of abuse in childhood 53 . This classic gene × environment effect was described not only in terms of behavior and clinical symptoms, but also at the level of neural circuit function. FKBP5 risk variants have been found to be associated with an exaggerated amygdala response to threat in individuals having suffered emotional neglect 54 . Moreover, a comprehensive series of experiments in rodents, led by Binder and colleagues among others, detailed a mechanism by which FKBP5 acts to reduce the sensitivity of the glucocorticoid receptor to cortisol. Together these observations present a model whereby an FKPB5 gene variation regulates brain activity to buffer the effects of stress and mitigate risk for stress related disorders 55 . The identification of the glucocorticoid system as central to these effects also brings us full circle to the work originated by Selye almost a century earlier.
Toward biomarkers of risk for stress-related disorders
As in other areas of psychiatry, and medicine more broadly, the hope has been that a growing knowledge base of genes that reliably predict stressrelated phenotypes would allow us to forecast the Marina Corral Spence/Nature Publishing Group Figure 2 Preexisting variability in a highly conserved neural circuitry mediating stress responsiveness predicts vulnerability for stress-related dysfunction. Top, individual differences in human amygdala reactivity to threat-related facial expressions predict psychological vulnerability to future stress. Participants with relatively greater amygdala reactivity (red) are more likely to experience symptoms of depression and anxiety if they encounter stressors up to 4 years later 58 . Bottom, individual differences in the volume of the basolateral amygdala in mice predict sensitivity to fear conditioning. Mice with a smaller basolateral amygdala (red) are more likely to express relatively high conditioned fear 59 .
npg p e r s p e c t i v e likelihood someone will succumb to a stress related disorder. We have not yet reached this point, and there remain no definitive genetic markers 41 , but the outlook may improve as the results of highly powered genome wide association studies (GWAS) emerge. Additionally, there are initial signs that quan tifying individual differences in the structure and function of stressmediating neural cir cuits moderated by genes might be a tractable path toward 'neural biomarkers. ' Work along these lines remains at the earliest stages, but one encouraging recent observation has again involved variability in the human amygdala response to threat. In this research, premorbid amygdala hyperac tivity predicts the likelihood of succumbing to a stressrelated dis order, and does so independently of genetic or environmental risk. Separate studies have now shown that relatively exaggerated threat related amygdala reactivity is linked to greater risk for presenting with PTSDlike symptoms after combat exposure in soldiers 56 and the experience of a terrorist attack in civilians 57 . Recently, research in one of our laboratories extended these findings by demonstrating that higher threatrelated amygdala reactivity predicts broader risk for pathological mood and anxiety in response to common stressors, such as changing jobs or moving from home, that were experienced up to 4 years later 58 (Fig. 2) . Strikingly, the variability in the magni tude of amygdala reactivity was, independently, a better predictor of vulnerability than were differences in selfreported symptoms, recent stressful experiences or childhood trauma 58 .
Preclinical models, in which exposure to stressors can be care fully controlled and monitored throughout life, are in many ways ideally suited to study and elaborate on such premorbid neural risk biomarkers. However, a barrier to prospective studies of brain behavior associations in rodents is that precise analysis of neural anatomy and function is often performed ex vivo. This technical hurdle will be increasingly easy to overcome with the availability of higherresolution smallanimal imaging or technologies permitting chronic, repeated sampling of neuronal activity in the same animal. An alternative method is to take advantage of isogenic rodent strains exhibiting stable interindividual and intergenerational variation in a neural phenotype of interest, such that one cohort of mice from each strain can be subjected to neural analysis and another cohort to behavioral testing. Using this approach, we have shown that reduced total volume of the amygdala, but not other brain regions such as the hippocampus, serves as a good predictor of higher learned fear behavior in mice 59 (Fig. 2) . Here again, we find parallels in the human brain, where differences in the gray matter volume of the amygdala are reported across adults with stressrelated disorders, with at least one study suggesting that smaller amygdala volumes may predispose soldiers to combatrelated PTSD 60 .
Future work along these lines will be valuable for defining a set of neural biomarkers that, when considered individually or collectively, has the power to reliably predict any given person's susceptibility to stressrelated illness. Likewise, the identification of specific genetic and epigenetic differences in rodents that account for variation in stressrelated behaviors could prove key to pinpointing novel targets for studies in humans. This is not just an intellectual ques tion, but a practical consideration, given that neuroimagingbased assessment of neural biomarkers is highly unlikely to be available in routine clinical settings. Continued translational research will help establish reliable genetic, epigenetic and molecular markers of riskrelated neural circuit function that can be readily assayed from peripheral tissues, such as blood and saliva, and serve as routine proxies of individual risk.
Advancing treatment of stress-related disorders
As is true across all of medicine, treatment of mental illness is costly, inefficient and, in the end, largely inadequate for a significant pro portion of patients. The ultimate value of biomarkers is to provide a means to prevent stressrelated disorders from developing in the first place. In the interim, the value of translational research lies in the development of more effective strategies for treatment. So has the remarkable pace of translational discoveries in stressrelated research borne therapeutic fruit? Over the course of a halfcentury of research, involving 10,000 preclinical experiments on around 1,500 compounds, there has been a remarkable paucity of novel anxiolytic compounds that have successfully moved from the laboratory to the clinic 61 .
Much has been said about the reasons for this apparent failure and the fact that the blame should not be apportioned solely to the poor predictive validity of our animal models. Even targets with significant therapeutic potential in animal studies can often be challenging to 'make druggable' and, even after they are, may turn out to be unsafe or poorly tolerated in patients. There is also the somewhat contentious issue of whether the current structure of clinical trials is truly optimal for identifying new drugs, particularly those that are not necessar ily more effective than approved treatments but do have a superior sideeffect profile. Nonetheless, we clearly need to improve upon the drug process of discovering new antistress medications and, as we have outlined here, we are confident that the growing trend toward 'joined up' translational research that exploits the power of basic neuroscience tools, neuroimaging and detailed clinical profiling can move the field forward.
Here, it is important to consider how translational research can also encourage nonpharmaceutical approaches to treatment, including cognitive restructuring and direct, nondrug manipulation of neural Clinical disorders or clinically relevant outcomes Figure 3 Translational research has revealed convergent processes at multiple levels of analysis associated with the stress-related disorders.
npg p e r s p e c t i v e stress circuits. One example of the former comes from observations in rodents and humans that extinctioninduced reductions in cue elicited anxiety and associated amygdala responses can be improved with relatively simple modifications to behavioral procedures [62] [63] [64] .
Targeting the neural circuits that support fear learning and stress responsiveness has also already provided compelling therapeutic findings. Most appealingly, noninvasive methods such as repetitive transcranial magnetic stimulation (rTMS) have been successfully used to manipulate neural circuits implicated in the pathophysiology of stressrelated disorders 65 . For example, rTMS targeting the dorsola teral PFC, which is positioned to affect explicit topdown regulatory control of the amygdala via connections through the medial PFC, has resulted in reduced behavioral symptoms and HPAaxis reactiv ity associated with hyperarousal in patients with PTSD 66 . It will be interesting to see whether equally effective outcomes may be possible with even more accessible, noninvasive techniques such as transcra nial direct current stimulation (tDCS) 67 .
Though less applicable to all but the most severe cases, invasive techniques can get us even closer to the neural circuit nodes identi fied through translational research. Most prominent amongst these approaches is deep brain stimulation (DBS), wherein depth electrodes controlled by a subcutaneous pacemaker are implanted through stere otactic neurosurgery in target regions of interest 68 . Unlike rTMS or tDCS, the effectiveness of which is limited to the cortical mantle just below the skull, DBS can target any brain structure. For example, based on translational research, areas adjacent to the ventromedial PFC are common targets in the DBS treatment of depression that can provide relief from lifelong debilitating illness in otherwise treatment resistant patients 69 . Although this is as yet untested, there is hope that DBS could provide therapeutic options in severe cases of other stressrelated disorders, including PTSD.
It is further possible that invasive techniques such as DBS may one day allow direct translation of the increasingly precise mapping of neural circuits governing fear learning and stress responsiveness in preclinical models. Of course, such applications are predicated on convincingly demonstrating that analogous circuits exist in the human brain. Although this may be possible with human functional neuroimaging at higher anatomical resolution using greater magnetic field strengths, many methodological challenges remain before such advances may be achieved. In the end, however, successful access to, and therapeutic manipulation of, an increasingly complex and finescale neural circuitry in humans may only be made possible by expanding the catalog of druggable targets.
Concluding remarks
In addition to the highly conserved biological machinery positioned to adaptively manage ubiquitously experienced stress, the ability to employ essentially identical behavioral measures, such as fear con ditioning and extinction paradigms, that produce parallel metrics of corticolimbic circuit function and recruit analogous molecular and genetic factors has driven translational discoveries in stressrelated disorders (Fig. 3) . Translational stress research is thus positioned to be a standard bearer for the charge toward the recasting of mental illness as manifestations of disordered brain circuits and the behavioral pro cesses they subserve, as formalized in the National Institute of Mental Health's Research Domain Criteria (RDoC) initiative 70 . Though not all mental disorders might prove ready fertile ground for such rapid and convergent discoveries, preclinical models have been developed for a wide range of disorders including drug addiction, depression, autism and even schizophrenia. By emphasizing common environmental demands and resulting conservation of neural, physiological and behavioral response repertoires across species, translational efforts around these disorders could find significant traction as they have in the field of stress research.
